ABS 2019: Growing Your Practice, Cesium Data & The Power of Blu

ABS 2019: Growing Your Practice, Cesium Data & The Power of Blu

Isoray was proud to be a part of yet another annual meeting for the American Brachytherapy Society (ABS) in Miami and, as we’ve had some time to process all of the stimulating conversations and unique opportunities that ABS always provides, we’d like to highlight some...

Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies

RICHLAND, WASHINGTON – August 13, 2019 – Studies recently reported at scientific meetings and published in medical journals illustrate that Isoray, Inc.’s (NYSE AMERICAN: ISR) Cesium Blu™ is making an important difference in providing treatment options for cancer...

Isoray Announces Second Quarter Fiscal 2019 Financial Results

Record Revenue and Gross Profit Revenue Increased 24% Year-Over-Year   RICHLAND, WASHINGTON – February 12, 2019 — Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...